Combination therapies go head to head

Article

Azarga (brinzolamide 1%/timolol 0.5% eye drops suspension; Alcon) and Cosopt (dorzolamide 2%/timolol 0.5% eye drops solution; Merck) are equally efficacious in IOP-lowering capacity, however, Azarga offers greater ocular comfort, according to a study presented at this week?s European Glaucoma Society congress in Berlin, Germany.

Azarga (brinzolamide 1%/timolol 0.5% eye drops suspension; Alcon) and Cosopt (dorzolamide 2%/timolol 0.5% eye drops solution; Merck) are equally efficacious in IOP-lowering capacity, however, Azarga offers greater ocular comfort, according to a study presented at this week's European Glaucoma Society congress in Berlin, Germany.

A team led by Dr Gianluca Manni of the University of Roma Tor Vergata, Rome, Italy, performed a one-year, multicentre, randomized, double-masked, active controlled, parallel group comparison of the two combination therapies, Azarga and Cosopt in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT) who required additional therapy. Four hundred and thirty seven patients were enrolled in centres in Italy, France, Belgium, Singapore, Lithuania, Sweden or the UK.

The treatment phase and IOP assessments included visits at week two, months three, six, nine and 12. Of the 437 patients enrolled, 220 received Azarga and 217 Cosopt.

The investigators found the treatments to have comparable IOP-lowering efficacy, with IOP reductions from baseline ranging from 7.2 to 9.2 mmHg in the Azarga group (mean IOP range 16.7 to 18.8 mmHg) and from 7.4 to 8.9 mmHg for Cosopt (mean IOP range 16.9 to 19.4 mmHg). Up to 60% and 59% of patients had IOP

Although the investigators reported a similar safety profile amongst both groups, Azarga did show a local comfort advantage over Cosopt in terms of ocular irritation (2.7% vs 10.6%) and ocular pain (2.7% vs 6.5%).

The researchers concluded that, although the two combination therapies were equally efficacious in their ability to lower IOP in OAG or OHT patients, Azarga showed greater local ocular comfort when compared with Cosopt.

Recent Videos
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
Paulo Antonio Silva, Associate Professor of Ophthalmology at Harvard Medical School
Intraocular Pressure Outcomes Following Suprachoroidal Triamcinolone Acetonide in Patients With Glaucoma, Ocular Hypertension, or Steroid Response
Durga Borkar, MD, MMCi, discusses FAS inhibition with ONL-1204
Theodore Leng, MD, MS, speaks about 12-Month Real-World Clinical and Anatomical Outcomes With Faricimab in Patients With Diabetic Macular Edema:The FARETINA-DME Study
Rishi P. Singh, MD, discussed his presentation on the results from part 1 of the Phase 2/3 SIGLEC trial assessing AVD-104 for GA
Carl C. Awh, MD, FASRS, speaks with Hattie Hayes of Ophthalmology Times Europe
Carl J. Danzig, MD
Martin Zinkernagel, MD, PhD, speaks about the ASRS sustainability expert panel
Srinivas Sai Kondapalli, MD, discusses outer retinal tubulations in lesion growth for subfoveal and non-subfoveal GA
© 2024 MJH Life Sciences

All rights reserved.